Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (628) Arrow Down
Filter Results: (628) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (1,054)
    • People  (3)
    • News  (261)
    • Research  (628)
    • Events  (1)
    • Multimedia  (6)
  • Faculty Publications  (299)

Show Results For

  • All HBS Web  (1,054)
    • People  (3)
    • News  (261)
    • Research  (628)
    • Events  (1)
    • Multimedia  (6)
  • Faculty Publications  (299)
← Page 12 of 628 Results →
Sort by

Are you looking for?

→Search All HBS Web
  • March 2015 (Revised February 2022)
  • Supplement

CV Ingenuity (B): Epilogue

By: Regina E. Herzlinger and Andrew Otazo
Duke Rohlen used a lea-nfunding, iconoclastic strategy for his start up for a drug eluding balloon for peripheral artery disease. His giant competitors were first movers. Did Duke obtain the funding he sought? How did his DEB fare versus that of his competitors? The... View Details
Keywords: CV Ingenuity; CVI; Drug Eluting Balloon; DEB; Drug Eluting Stent; Angioplasty Balloon; FoxHollow; Medical Device; Medical Device Startup; Premarket Approval; PMA; Lutonix; Stellarex; LEVANT; ILLUMENATE; Clinical Trials; Peripheral Arterial Disease; PAD; Healthcare Startups; Covidien; Health Care and Treatment; Health Testing and Trials; Business Startups; Commercialization; Strategy; Health Industry; Health Industry; United States; Europe
Citation
Purchase
Related
Herzlinger, Regina E., and Andrew Otazo. "CV Ingenuity (B): Epilogue." Harvard Business School Supplement 315-087, March 2015. (Revised February 2022.)
  • March 2024
  • Article

Investigation of Divergent Thinking among Surgeons and Surgeon Trainees in Canada (IDEAS): A Mixed-methods Study

By: Alex Thabane, Tyler McKechnie, Vikram Arora, Goran Calic, Jason W Busse, Ranil Sonnadara and Mohit Bhandari
Objective: To assess the creative potential of surgeons and surgeon trainees, as measured by divergent thinking. The secondary objectives were to identify factors associated with divergent thinking, assess confidence in creative problem-solving and the perceived effect... View Details
Keywords: Creativity; Cognition and Thinking; Surveys; Health Industry
Citation
Register to Read
Related
Thabane, Alex, Tyler McKechnie, Vikram Arora, Goran Calic, Jason W Busse, Ranil Sonnadara, and Mohit Bhandari. "Investigation of Divergent Thinking among Surgeons and Surgeon Trainees in Canada (IDEAS): A Mixed-methods Study." BMJ Open 14, no. 3 (March 2024).
  • 10 Oct 2017
  • First Look

First Look at New Research and Ideas, October 10, 2017

in the diabetic space, became MannKind’s marketing partner and helped launch Afrezza in February, 2015. Although the drug had a black box warning and required doctors to perform a lung View Details
Keywords: Sean Silverthorne
  • April 2014 (Revised July 2015)
  • Case

Sanofi Pasteur: The Dengue Vaccine Dilemma

By: V. Kasturi Rangan, David E. Bloom, Vincent Dessain and Emilie Billaud
In 2012, Sanofi Pasteur was racing to develop a vaccine against dengue, a mosquito-borne disease, and was evaluating this product in a Phase IIb trial conducted with school children in Thailand. But while the candidate vaccine met the high safety expectations and a... View Details
Keywords: Health Testing and Trials; Product Launch; Market Entry and Exit; Emerging Markets; Pharmaceutical Industry; France
Citation
Educators
Purchase
Related
Rangan, V. Kasturi, David E. Bloom, Vincent Dessain, and Emilie Billaud. "Sanofi Pasteur: The Dengue Vaccine Dilemma." Harvard Business School Case 514-074, April 2014. (Revised July 2015.)
  • 16 Oct 2013
  • Op-Ed

Response to Readers: Combating Climate Change with Nuclear Power and Fracking

deaths due to severe smog (estimated between 3,000 to more recently 10,000 in London between December 1952 and March 1953) now officially acknowledged and seemingly routine in China today as well as coal... View Details
Keywords: by Joe Lassiter; Energy; Utilities
  • 01 Aug 2017
  • First Look

First Look at New Research and Ideas, August 1

Abstract—Objective: Assess whether a commitment contract informed by behavioral economics leads to persistent virologic suppression among HIV-positive patients with poor antiretroviral therapy (ART) adherence. Design: Single-center pilot randomized clinical View Details
Keywords: Sean Silverthorne
  • 16 May 2017
  • First Look

First Look at New Ideas and Research, May 16

health of the enterprise rather than near-term returns to its shareholders. Their model would refocus companies’ attention to innovation, strategic renewal, and investment in the future. Publisher's link:... View Details
Keywords: Re: Multiple Faculty
  • February 2009
  • Case

Avid Radiopharmaceuticals: The Venture Debt Question

By: Matthew Rhodes-Kropf and Ann Leamon
The CEO of a promising biotech company must decide how to respond to the macro-economic slump of late 2008. He had planned to pursue an aggressive schedule, moving the firm's Alzheimer's and Parkinson's disease imaging compounds through clinical trials and into the... View Details
Keywords: Financial Crisis; Entrepreneurship; Borrowing and Debt; Venture Capital; Financial Management; Investment; Health Testing and Trials; Expansion; Biotechnology Industry; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Rhodes-Kropf, Matthew, and Ann Leamon. "Avid Radiopharmaceuticals: The Venture Debt Question." Harvard Business School Case 809-086, February 2009.
  • 28 May 2019
  • Research & Ideas

Investor Lawsuits Against Auditors Are Falling, and That's Bad News for Capital Markets

mistake made. Our tests show that previously when there have been serious restatements of financials, those mistakes would lead to a certain number of lawsuits being filed and a certain settlement amount... View Details
Keywords: by Martha Lagace; Financial Services; Accounting
  • 17 Oct 2017
  • First Look

First Look at New Research and Ideas, October 17, 2017

patient satisfaction, and problems with patient safety. Nearly all U.S. health care organizations have used similar evidence to justify their investments in safety and quality.... View Details
Keywords: Sean Silverthorne
  • 23 May 2017
  • First Look

First Look at New Ideas and Research: May 23, 2017

about the causes of regional variations in health care expenditures. We use vignettes from patient and physician surveys linked to fee-for-service Medicare expenditures to test... View Details
Keywords: Carmen Nobel
  • 13 Jul 2020
  • Research & Ideas

Merck CEO Ken Frazier Discusses a COVID Cure, Racism, and Why Leaders Need to Walk the Talk

criminal justice reform, other issues like that, health care reform, but the nexus between corporate America and what Black America needs and the most, in my opinion, is... View Details
Keywords: by Staff; Pharmaceutical
  • November 2023 (Revised April 2024)
  • Case

BiomX: Bringing Phage Back to the Stage

By: Paul A. Gompers, Elie Ofek, Orna Dan and Emilie Billaud
In the spring of 2023, and following the favorable results of a trial involving its phage cocktail for treating lung infections among cystic fibrosis (CF) patients, the leadership of BiomX had several critical issues to wrestle with. First, given its precarious... View Details
Keywords: Working Capital; Financing and Loans; Health Testing and Trials; Product Development; Research and Development; Science-Based Business; Commercialization; Biotechnology Industry; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Gompers, Paul A., Elie Ofek, Orna Dan, and Emilie Billaud. "BiomX: Bringing Phage Back to the Stage." Harvard Business School Case 524-051, November 2023. (Revised April 2024.)
  • 2008
  • Article

Entrepreneurial Ventures and Whole-body Donations: A Regional Perspective from the United States

By: Michel Anteby and Mikell Hyman

Human cadavers are crucial to medical science. While the debate on how to secure sufficient cadavers has focused primarily on donors' behaviors, procuring organizations' roles in increasing donations remain less explored. The United States offers a unique setting in... View Details

Keywords: Entrepreneurship; Behavior; Programs; Nonprofit Organizations; Business Ventures; Health Testing and Trials; Demand and Consumers; Supply Chain; For-Profit Firms; Organizations; Training; United States
Citation
Find at Harvard
Read Now
Related
Anteby, Michel, and Mikell Hyman. "Entrepreneurial Ventures and Whole-body Donations: A Regional Perspective from the United States." Social Science & Medicine 66, no. 4 (2008): 963–969.
  • 2006
  • Chapter

BioRisk: interleukin-2 from laboratory to market in the United States and Germany

By: Arthur A. Daemmrich
Keywords: Product Development; Risk and Uncertainty; Health Testing and Trials; Pharmaceutical Industry; Biotechnology Industry; United States; Germany
Citation
Related
Daemmrich, Arthur A. "BioRisk: interleukin-2 from laboratory to market in the United States and Germany ." In The Risks of Medical Innovation: Risk Perception and Assessment in Historical Context, edited by Thomas Schlich and Ulrich Tröhler, 242–261. Routledge, 2006.
  • 06 Feb 2018
  • First Look

First Look at New Research and Ideas: February 6, 2018

communities) and the moderating effects of team leader experience. We test our moderated mediation model in a sample of 121 teams that filed patents in a Fortune 50 company’s India R&D center between... View Details
  • 26 Sep 2017
  • First Look

First Look at New Research and Ideas, September 26, 2017

article proposes that the review process initially be adopted on a pilot basis. Publisher's link: https://www.hbs.edu/faculty/Pages/item.aspx?num=53264 September 2017 Health Affairs Narrow Networks on the View Details
Keywords: Sean Silverthorne
  • 18 Apr 2018
  • First Look

First Look at New Research and Ideas, April 18, 2018

18.2%—an effect driven by substitution of water for sugary drinks. Study 2 showed that graphic warning labels work by heightening negative affect and prompting consideration of health consequences. Study 3... View Details
Keywords: Sean Silverthorne
  • 14 Jul 2020
  • Research & Ideas

Restarting Under Uncertainty: Managerial Experiences from Around the World

At the start of the pandemic, the uncertainty primarily concerned health issues—the diffusion of the virus and its effective threat. As the virus expanded from China to other countries, the uncertainty... View Details
Keywords: by Raffaella Sadun, Andrea Bertoni, Alexia Delfino, Giovanni Fassio, and Mariapaola Testa
  • 24 Apr 2018
  • First Look

First Look at New Research and Ideas, April 24, 2018

and financial outcomes. The study complements financial education with (1) financial incentives on a financial literacy test to affect participant motivation, (2) financial goal setting to provide a... View Details
Keywords: Sean Silverthorne
  • ←
  • 12
  • 13
  • …
  • 31
  • 32
  • →

Are you looking for?

→Search All HBS Web
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College.